DOCSLIB.ORG

Mature Cells Can Be Reprogrammed to Become Pluripotent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mature Cells Can Be Reprogrammed to Become Pluripotent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`GC"@A%-0.&"GC<"M&"$/041"+48/" 89/F"(9+("(9&"&))%$%&'$:"/)"'0$4&+.".&6./-.+33%'-"$/041";&"-.&+(4:"%36./5&1";:"6&.)/.3%'-"8&.%+4" (.+'864+'(+(%/'8<"*:"(9%8"8(.+(&-:7"9&"89/F&1"(9+("+".+(9&."4+.-&"6./6/.(%/'"/)"+44"%'(&8(%'+4"&6%(9&4%+4" $&44"'0$4&%"$/041";&".&6./-.+33&1"@[0.1/'7"!O`GC<" [0.1/'" $/'$401&1" (9+(" 1%))&.&'(%+(&1" 8/3+(%$" $&44"'0$4&%"9+1"(9&"6/(&'(%+4"(/".&5&.("(/"640.%6/(&'$:<"M/F&5&.7"$/'8%1&.+;4&"(%3&"6+88&1";&)/.&"9%8" 1%8$/5&.:"-+%'&1";./+1"+$$&6(+'$&"%'"(9&"8$%&'(%)%$"$/330'%(:<"='"80;8&>0&'("&?6&.%3&'(87"[0.1/'" 08&1"'0$4&%")./3"+104(")./-8"(/"-&'&.+(&"(+16/4&87"+'1"$/'5&.8&4:7"&3;.:/'%$"1%))&.&'(%+(&1"'0$4&%" 8066/.(&1"1&5&4/63&'("/)"+104(")./-8"@[0.1/'"+'1"a&94%'-&.7"!O``b"c+8,&:"+'1"[0.1/'7"!OQdC<"" " [0.1/'e8"1%8$/5&.:"F+8"+")0'1+3&'(+4"6+.+1%-3"89%)(7"89/F%'-")/."(9&")%.8("(%3&"(9+("(9&"$&44"'0$4&08" )./3"+"8/3+(%$"1%))&.&'(%+(&1"$&44"F+8"&'1/F&1"F%(9"(9&"$+6+$%(:"(/"1.%5&"1&5&4/63&'("%'(/"+")044" .+'-&"/)"8/3+(%$"$&44"(:6&8"+'1"(%880&8"+)(&.";&%'-"64+$&1"%'"(9&"$:(/64+83%$"3%4%&0"/)"+'"&--"$&44<"" " 42/%&'! 8! Z/9'" [0.1/'" 08&1"aR"4%-9("@!C"(/"1&8(./:"(9&"$&44"'0$4&08"%'"+")./-"&--<"M&"(9&'".&64+$&1"(9&"&--" '0$4&08"F%(9"+"$&44"'0$4&08")./3"+"1%))&.&'(%+(&1"%'(&8(%'+4"&6%(9&4%+4"$&44")./3"+"(+16/4&"@GC<"J+':"3+'%604+(&1" &--8"1%1"'/("1&5&4/6";0("%'"8&5&.+4"$+8&8"'/.3+4"8F%33%'-"(+16/4&8"F&.&"-&'&.+(&1"@UC<"D9%8"89/F&1"(9+("(9&" -&'&(%$"%')/.3+(%/'".&>0%.&1"(/"-&'&.+(&"(9&"1%))&.&'(%+(&1"$&448"%'"+"(+16/4&".&3+%'&1"%'(+$("%'"(9&"1/'/."$&44" '0$4&08<"c+(&."8(01%&8"9+5&"89/F'"(9+("+48/"3+33+48"$+'";&"$4/'&1";:"(9%8"(&$9'%>0&"@_C<! ! 4%&$9'&!1':').-0'+$*!.7!&'-&./&#002+/!,;!+%()'#&!$&#+*7'&! " [0.1/'e8"1%8$/5&.:"%'(./10$&1"+"'&F".&8&+.$9")%&41"$&'(&.&1"/'"8/3+(%$"$&44"'0$4&+."(.+'8)&."@#LSDC" +8" +" 3&(9/1" (/" 0'1&.8(+'1" .&6./-.+33%'-"
Load more

Recommended publications
  • Determination of Cell Development, Differentiation and Growth
    Pediat. Res. I: 395-408 (1967) Determination of Cell Development, Differentiation and Growth A Review D.M.BROWN[ISO] Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA Introduction plasmic synthesis, water uptake, or, in the case of intact tissue, intercellular deposition. It may include prolifera­ It has become increasingly apparent that the basis for tion or the multiplication of identical cells and may be biologic variation in relation to disease states is in accompanied by differentiation which implies anatomical large part predetermined from early embryonic stages. as well as functional changes. The number of cellular Consideration of variations of growth and development units in a tissue may be related to the deoxyribonucleic must take into account the genetic constitution and acid (DNA) content or nucleocytoplasmic units [24, early embryonic events of tissue and organ develop­ 59, 143]. Differentiation may refer to physical and ment. chemical organization of subcellular components or The incidence of congenital malformation has been to changes in the structure and organization of cells estimated to be 2 to 3 percent of all live born infants and leading to specialized organs. may double by one year [133]. Minor abnormalities are even more common [79]. Furthermore, the large variety of well-defined 'inborn errors of metabolism', Control of Embryonic Chemical Development as well as the less apparent molecular and chromosomal abnormalities, should no doubt be considered as mal­ Protein syntheses during oogenesis and embryogenesis formations despite the possible lack of gross somatic are guided by nuclear and nucleolar ribonucleic acid aberrations. Low birth weight is a frequent accom­ (RNA) which are in turn controlled by primer DNA.
    [Show full text]
  • Stem Cells Cloning Prons & Cons
    & Trans g ge in n n e s o l i s C Cloning and Transgenesis Kalodimou, Clon Transgen 2014, 3:3 ISSN: 2168-9849 DOI: 10.4172/2168-9849.1000127 Short Communication Open Access Stem Cells Cloning Prons & Cons Vasiliki E Kalodimou* Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece *Corresponding author: Vasiliki E Kalodimou, Head of Flow Cytometry-Research and Regenerative Medicine Department, IASO Maternity Hospital, Athens, Greece, Tel: 0030-210-618-5; E-mail: [email protected] Rec date: May 16, 2014; Acc date: Jun 30, 2014; Pub date: July 2, 2014 Copyright: © 2014 Kalodimou VE. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Stem Cell Cloning the target cell. In principle, this may be dangerous, because the gene therapy vector can potentially modify the activity of neighboring genes Over the last several decades, the ideas of both stem cell research (positively or negatively) in close proximity to the insertion site or and cloning have received significantly more attention than ever even inactivate host genes by integrating into them [6]. These before; currently there are 23 open/completed clinical trials, together phenomena may contribute to the malignant transformation of the with a great deal of controversy. This new advances in medical targeted cells, ultimately resulting in cancer. Another major limitation technology had provide scientific with a new view of potential to help of using adult stem cells is that it is relatively difficult to maintain the people suffering from various diseases as well as to help them recover stem cell state during ex vivo manipulations.
    [Show full text]
  • Human Cloning: Must We Sacrifice Medical Research in the Name of a Total Ban?
    S. HRG. 107–812 HUMAN CLONING: MUST WE SACRIFICE MEDICAL RESEARCH IN THE NAME OF A TOTAL BAN? HEARING BEFORE THE COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ONE HUNDRED SEVENTH CONGRESS SECOND SESSION FEBRUARY 5, 2002 Serial No. J–107–55 Printed for the use of the Committee on the Judiciary ( U.S. GOVERNMENT PRINTING OFFICE 83–684 PDF WASHINGTON : 2002 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC COMMITTEE ON THE JUDICIARY PATRICK J. LEAHY, Vermont, Chairman EDWARD M. KENNEDY, Massachusetts ORRIN G. HATCH, Utah JOSEPH R. BIDEN, JR., Delaware STROM THURMOND, South Carolina HERBERT KOHL, Wisconsin CHARLES E. GRASSLEY, Iowa DIANNE FEINSTEIN, California ARLEN SPECTER, Pennsylvania RUSSELL D. FEINGOLD, Wisconsin JON KYL, Arizona CHARLES E. SCHUMER, New York MIKE DEWINE, Ohio RICHARD J. DURBIN, Illinois JEFF SESSIONS, Alabama MARIA CANTWELL, Washington SAM BROWNBACK, Kansas JOHN EDWARDS, North Carolina MITCH MCCONNELL, Kentucky BRUCE A. COHEN, Majority Chief Counsel and Staff Director SHARON PROST, Minority Chief Counsel MAKAN DELRAHIM, Minority Staff Director (II) VerDate Feb 1 2002 09:13 Jan 16, 2003 Jkt 083684 PO 00000 Frm 00002 Fmt 5904 Sfmt 5904 C:\HEARINGS\83684.TXT SJUD4 PsN: CMORC C O N T E N T S STATEMENTS OF COMMITTEE MEMBERS Page Brownback, Hon.
    [Show full text]
  • 書 名 等 発行年 出版社 受賞年 備考 N1 Ueber Das Zustandekommen Der
    書 名 等 発行年 出版社 受賞年 備考 Ueber das Zustandekommen der Diphtherie-immunitat und der Tetanus-Immunitat bei thieren / Emil Adolf N1 1890 Georg thieme 1901 von Behring N2 Diphtherie und tetanus immunitaet / Emil Adolf von Behring und Kitasato 19-- [Akitomo Matsuki] 1901 Malarial fever its cause, prevention and treatment containing full details for the use of travellers, University press of N3 1902 1902 sportsmen, soldiers, and residents in malarious places / by Ronald Ross liverpool Ueber die Anwendung von concentrirten chemischen Lichtstrahlen in der Medicin / von Prof. Dr. Niels N4 1899 F.C.W.Vogel 1903 Ryberg Finsen Mit 4 Abbildungen und 2 Tafeln Twenty-five years of objective study of the higher nervous activity (behaviour) of animals / Ivan N5 Petrovitch Pavlov ; translated and edited by W. Horsley Gantt ; with the collaboration of G. Volborth ; and c1928 International Publishing 1904 an introduction by Walter B. Cannon Conditioned reflexes : an investigation of the physiological activity of the cerebral cortex / by Ivan Oxford University N6 1927 1904 Petrovitch Pavlov ; translated and edited by G.V. Anrep Press N7 Die Ätiologie und die Bekämpfung der Tuberkulose / Robert Koch ; eingeleitet von M. Kirchner 1912 J.A.Barth 1905 N8 Neue Darstellung vom histologischen Bau des Centralnervensystems / von Santiago Ramón y Cajal 1893 Veit 1906 Traité des fiévres palustres : avec la description des microbes du paludisme / par Charles Louis Alphonse N9 1884 Octave Doin 1907 Laveran N10 Embryologie des Scorpions / von Ilya Ilyich Mechnikov 1870 Wilhelm Engelmann 1908 Immunität bei Infektionskrankheiten / Ilya Ilyich Mechnikov ; einzig autorisierte übersetzung von Julius N11 1902 Gustav Fischer 1908 Meyer Die experimentelle Chemotherapie der Spirillosen : Syphilis, Rückfallfieber, Hühnerspirillose, Frambösie / N12 1910 J.Springer 1908 von Paul Ehrlich und S.
    [Show full text]
  • Strategies and Experiences to Improve Research Uptake: the Royal Society and UK Science Funding
    Strategies and experiences to improve research uptake: The Royal Society and UK science funding Wider context Credit crunch UK Government Deficit New government Spending cuts The Royal Society Advisory Group Sir Martin Taylor FRS (Chair), Former Vice-President and Physical Secretary, The Royal Society Professor Glynis Breakwell, Vice-Chancellor, University of Bath Professor Ann Dowling DBE CBE FRS FREng, Professor of Engineering, University of Cambridge Sir Martin Evans FRS, Director, Cardiff School of Biosciences Sir Richard Friend FRS. Professor of Physics, University of Cambridge Professor Rachel Griffith FBA, Deputy Research Director, Institute for Fiscal Studies Professor Wendy Hall DBE FREng FRS, Professor of Computer Science, University of Southampton Dr Emily Holmes, Department of Psychiatry, University of Oxford Professor Richard Jones FRS, Professor of Physics, Sheffield University Professor Ben Martin, Science and Technology Policy Research Unit (SPRU) Paul Mountford, President, Emerging Markets, Cisco Professor Helga Nowotny, Vice-President, European Research Council Sir Paul Nurse FRS, President, Rockefeller University, New York City Dr David Roblin, Vice-President Global R&D, Pfizer Lord Sainsbury of Turville FRS, Gatsby Charitable Foundation Lord Waldegrave of North Hill, Provost, Eton College Sir Mark Walport, Director of the Wellcome Trust Sir Alan Wilson FRS FBA, Chairman, Arts and Humanities Research Council 7 Engagement across the political spectrum Lord Sainsbury of Turville FRS, Lord Waldegrave of North Hill, Conservative Labour Public R&D expenditure, 1970-2007 The UK punches above its weight The Cambridge phenomenon People in and outside science Global competition Average annual growth in R&D budgets, 1997-2007 ‘By the end of 2020…China will join the ranks of the world’s most innovative countries’ President Hu Jintao, Jan 2006 Investing in the downturn 0.60% 0.50% 0.40% Green technology R&D 0.30% GDP 0.20% 0.10% 0.00% Finland Norway Canada Portugal Germany Sweden USA Recommendations 1.
    [Show full text]
  • Biochemistry, Genetics, Molecular and Cell Biology) Hit the Newspaper Headlines on a Weekly Basis
    The Tenovus-Scotland Symposia and Medal Lectures Today medical advances as a result of discoveries in the Life Sciences (Biochemistry, Genetics, Molecular and Cell Biology) hit the newspaper headlines on a weekly basis. This was not the case at the time of the first Tenovus-Scotland Symposium nearly 35 years ago. Since the discovery of the structure of DNA twenty years earlier, great advances had been made in understanding, at the level of molecules, how genes work in the cell. From study of simple bacteria and viruses, it was known that the information for making all the different proteins in the cell was encoded in the sequence of nucleotides, the individual chemical units of DNA, but study of higher organisms seemed impossibly complex. The chromosomes in each human cell have about 23,000 genes in their DNA that contains a total of about three thousand million nucleotides - how would it be possible to study these genes individually? Three staff from the Biochemistry Department and the Beatson Institute planned a two day meeting at Glasgow University in 1974 to bring together scientists to discuss and learn about the new discoveries that were beginning to provide answers to that fundamental question. Sir Charles Illingworth, who had recently founded Tenovus- Scotland, saw the importance of these studies and their potential future application in medicine and agreed a grant towards the cost of the meeting, which we called the Tenovus-Scotland Symposium although the First Meeting was also jointly sponsored by the Nucleotide Group of the
    [Show full text]
  • Functional Skeletal Muscle Constructs from Transdifferentiated Human Fibroblasts
    www.nature.com/scientificreports OPEN Functional skeletal muscle constructs from transdiferentiated human fbroblasts Bin Xu1, Allison Siehr1 & Wei Shen1,2,3* Transdiferentiation of human non-muscle cells directly into myogenic cells by forced expression of MyoD represents one route to obtain highly desirable human myogenic cells. However, functional properties of the tissue constructs derived from these transdiferentiated cells have been rarely studied. Here, we report that three-dimensional (3D) tissue constructs engineered with iMyoD-hTERT- NHDFs, normal human dermal fbroblasts transduced with genes encoding human telomerase reverse transcriptase and doxycycline-inducible MyoD, generate detectable contractile forces in response to electrical stimuli upon MyoD expression. Withdrawal of doxycycline in the middle of 3D culture results in 3.05 and 2.28 times increases in twitch and tetanic forces, respectively, suggesting that temporally- controlled MyoD expression benefts functional myogenic diferentiation of transdiferentiated myoblast-like cells. Treatment with CHIR99021, a Wnt activator, and DAPT, a Notch inhibitor, leads to further enhanced contractile forces. The ability of these abundant and potentially patient-specifc and disease-specifc cells to develop into functional skeletal muscle constructs makes them highly valuable for many applications, such as disease modeling. Even though normal skeletal muscle has self-regenerative ability, it has remained a major challenge to treat genetic muscle diseases and volumetric muscle loss 1. Using human myogenic cells to develop cell-based thera- pies to repair or restore diseased or lost muscle tissue represents an important strategy to address this challenge. Human myogenic cells are also highly desirable for creating muscle tissue models or disease models, which can be used for fundamental studies of muscle physiology and pathology and for drug screening and validation.
    [Show full text]
  • Genomic Profiling Reveals High Frequency of DNA Repair Genetic
    www.nature.com/scientificreports OPEN Genomic profling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer Reham Abdel‑Wahab1,9, Timothy A. Yap2, Russell Madison4, Shubham Pant1,2, Matthew Cooke4, Kai Wang4,5,7, Haitao Zhao8, Tanios Bekaii‑Saab6, Elif Karatas1, Lawrence N. Kwong3, Funda Meric‑Bernstam2, Mitesh Borad6 & Milind Javle1,10* DNA repair gene aberrations (GAs) occur in several cancers, may be prognostic and are actionable. We investigated the frequency of DNA repair GAs in gallbladder cancer (GBC), association with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death protein 1 (PD‑1), and its ligand (PD‑L1) expression. Comprehensive genomic profling (CGP) of 760 GBC was performed. We investigated GAs in 19 DNA repair genes including direct DNA repair genes (ATM, ATR , BRCA1, BRCA2, FANCA, FANCD2, MLH1, MSH2, MSH6, PALB2, POLD1, POLE, PRKDC, and RAD50) and caretaker genes (BAP1, CDK12, MLL3, TP53, and BLM) and classifed patients into 3 groups based on TMB level: low (< 5.5 mutations/Mb), intermediate (5.5–19.5 mutations/Mb), and high (≥ 19.5 mutations/Mb). We assessed MSI status and PD‑1 & PD‑L1 expression. 658 (86.6%) had at least 1 actionable GA. Direct DNA repair gene GAs were identifed in 109 patients (14.2%), while 476 (62.6%) had GAs in caretaker genes. Both direct and caretaker DNA repair GAs were signifcantly associated with high TMB (P = 0.0005 and 0.0001, respectively). Tumor PD‑L1 expression was positive in 119 (15.6%), with 17 (2.2%) being moderate or high. DNA repair GAs are relatively frequent in GBC and associated with coexisting actionable mutations and a high TMB.
    [Show full text]
  • An Interview with John Gurdon Aidan Maartens*,‡
    © 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 1581-1583 doi:10.1242/dev.152058 SPOTLIGHT An interview with John Gurdon Aidan Maartens*,‡ John Gurdon is a Distinguished Group Leader in the Wellcome Trust/ Cancer Research UK Gurdon Institute and Professor Emeritus in the Department of Zoology at the University of Cambridge. In 2012, he was awarded the Nobel Prize in Physiology or Medicine jointly with Shinya Yamanaka for work on the reprogramming of mature cells to pluripotency, and his lab continues to investigate the molecular mechanisms of nuclear reprogramming by oocytes and eggs. We met John in his Cambridge office to discuss his career and hear his thoughts on the past, present and future of reprogramming. Your first paper was published in 1954 and concerned not embryology but entomology. How did that come about? Well, that early paper was published in the Entomologist’s Monthly Magazine. Throughout my early life, I really was interested in insects, and used to collect butterflies and moths. When I was an undergraduate I liked to take time off and go out to Wytham Woods near Oxford to see what I could find. So I went out one cold spring day and there were no butterflies about, nor any moths, but, out of nowhere, there was a fly – I caught it, put it in my bottle, and had a look at it. The first thing that was obvious was that it wasn’t a fly, it was a hymenopteran, but when I tried to identify it I simply could cells in the body have the same genes.
    [Show full text]
  • Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs Using Somatic Cell Nuclear Transfer Sharon J
    & Trans Harrison et al., Clon Transgen 2015, 4:2 g ge in n n e DOI: 10.4172/2168-9849.1000136 s o l i s C Cloning & Transgenesis ISSN: 2168-9849 Research Article Open Access Multipotent Cell Types in Primary Fibroblast Cell Lines Used to Clone Pigs using Somatic Cell Nuclear Transfer Sharon J. Harrison, Luke F.S. Beebe, Ivan Vassiliev, Stephen M. McIlfatrick and Mark B. Nottle* Reproductive Biotechnology Group, Centre for Stem Cell Research, Robinson Institute School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, South Australia, 5005, Australia Abstract We have previously demonstrated that the use of porcine mesenchymal stem cells (MSCs) isolated from the bone marrow can increase the proportion of somatic cell nuclear transfer (SCNT) embryos that develop to the blastocyst stage compared with adult fibroblasts obtained from the same animal. The aim of the present study was to determine if MSCs are also present in primary cultures of adult fibroblasts which are commonly used for cloning live animals. To do this we chose a primary culture of adult fibroblasts that we had previously used to clone pigs. Single cell clones were isolated using low-density plating. After seven days of culture 63% of colonies displayed typical fibroblast morphology, while the remainder appeared cobblestone-like in appearance. Two of the 57 clones that displayed fibroblast morphology differentiated into adipocytes but not chondrocytes or osteocytes (uni-potent clones). Three of the 33 cobblestone-like clones differentiated into chondrocytes only, while 3 differentiated into adipocytes and chondrocytes but not osteocytes (bi-potent clones). One of the bi-potent cobblestone-like clones was then used for SCNT and in vitro development compared with a fibroblast-like clone which did not differentiate.
    [Show full text]
  • Mitosis Vs. Meiosis
    Mitosis vs. Meiosis In order for organisms to continue growing and/or replace cells that are dead or beyond repair, cells must replicate, or make identical copies of themselves. In order to do this and maintain the proper number of chromosomes, the cells of eukaryotes must undergo mitosis to divide up their DNA. The dividing of the DNA ensures that both the “old” cell (parent cell) and the “new” cells (daughter cells) have the same genetic makeup and both will be diploid, or containing the same number of chromosomes as the parent cell. For reproduction of an organism to occur, the original parent cell will undergo Meiosis to create 4 new daughter cells with a slightly different genetic makeup in order to ensure genetic diversity when fertilization occurs. The four daughter cells will be haploid, or containing half the number of chromosomes as the parent cell. The difference between the two processes is that mitosis occurs in non-reproductive cells, or somatic cells, and meiosis occurs in the cells that participate in sexual reproduction, or germ cells. The Somatic Cell Cycle (Mitosis) The somatic cell cycle consists of 3 phases: interphase, m phase, and cytokinesis. 1. Interphase: Interphase is considered the non-dividing phase of the cell cycle. It is not a part of the actual process of mitosis, but it readies the cell for mitosis. It is made up of 3 sub-phases: • G1 Phase: In G1, the cell is growing. In most organisms, the majority of the cell’s life span is spent in G1. • S Phase: In each human somatic cell, there are 23 pairs of chromosomes; one chromosome comes from the mother and one comes from the father.
    [Show full text]
  • 2019 Annual Report
    BECKMAN CENTER 279 Campus Drive West Stanford, CA 94305 650.723.8423 Stanford University | Beckman Center 2019 Annual Report Annual 2019 | Beckman Center University Stanford beckman.stanford.edu 2019 ANNUAL REPORT ARNOLD AND MABEL BECKMAN CENTER FOR MOLECULAR AND GENETIC MEDICINE 30 Years of Innovation, Discovery, and Leadership in the Life Sciences CREDITS: Cover Design: Neil Murphy, Ghostdog Design Graphic Design: Jack Lem, AlphaGraphics Mountain View Photography: Justin Lewis Beckman Center Director Photo: Christine Baker, Lotus Pod Designs MESSAGE FROM THE DIRECTOR Dear Friends and Trustees, It has been 30 years since the Beckman Center for Molecular and Genetic Medicine at Stanford University School of Medicine opened its doors in 1989. The number of translational scientific discoveries and technological innovations derived from the center’s research labs over the course of the past three decades has been remarkable. Equally remarkable have been the number of scientific awards and honors, including Nobel prizes, received by Beckman faculty and the number of young scientists mentored by Beckman faculty who have gone on to prominent positions in academia, bio-technology and related fields. This year we include several featured articles on these accomplishments. In the field of translational medicine, these discoveries range from the causes of skin, bladder and other cancers, to the identification of human stem cells, from the design of new antifungals and antibiotics to the molecular underpinnings of autism, and from opioids for pain
    [Show full text]